These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 17060208)

  • 81. Five-year change in statistical designs of phase II trials published in leading cancer journals.
    Thezenas S; Duffour J; Culine S; Kramar A
    Eur J Cancer; 2004 May; 40(8):1244-9. PubMed ID: 15110889
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Phase II multi-step planning methods in oncology: comparison, recommendations and potential applications.
    Medioni J; de Rycke Y; Tournoux Facon C; Mallet A; Asselain B
    Contemp Clin Trials; 2007 May; 28(3):249-57. PubMed ID: 17113357
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Some design issues in trials of microbicides for the prevention of HIV infection.
    Fleming TR; Richardson BA
    J Infect Dis; 2004 Aug; 190(4):666-74. PubMed ID: 15272392
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.
    Sun X; Peng P; Tu D
    Contemp Clin Trials; 2011 Jan; 32(1):108-13. PubMed ID: 20888929
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Optimal designs for estimating the most successful dose.
    Zohar S; O'Quigley J
    Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A randomized two-stage design for phase II clinical trials based on a Bayesian predictive approach.
    Cellamare M; Sambucini V
    Stat Med; 2015 Mar; 34(6):1059-78. PubMed ID: 25545805
    [TBL] [Abstract][Full Text] [Related]  

  • 88. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A strategic framework for novel drug development in multiple myeloma.
    Anderson KC; Hannah AL; Pazdur R; Farrell AT
    Br J Haematol; 2007 Jul; 138(2):153-9. PubMed ID: 17593022
    [No Abstract]   [Full Text] [Related]  

  • 90. Methods of joint evaluation of efficacy and toxicity in phase II clinical trials.
    Tournoux C; De Rycke Y; Médioni J; Asselain B
    Contemp Clin Trials; 2007 Jul; 28(4):514-24. PubMed ID: 17331808
    [TBL] [Abstract][Full Text] [Related]  

  • 91. On the efficiency of targeted clinical trials.
    Maitournam A; Simon R
    Stat Med; 2005 Feb; 24(3):329-39. PubMed ID: 15551403
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Optimal two-stage designs for clinical trials based on safety and efficacy.
    Thall PF; Cheng SC
    Stat Med; 2001 Apr; 20(7):1023-32. PubMed ID: 11276033
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Multinomial phase II cancer trials incorporating response and early progression.
    Zee B; Melnychuk D; Dancey J; Eisenhauer E
    J Biopharm Stat; 1999 May; 9(2):351-63. PubMed ID: 10379698
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Curtailed two-stage designs in Phase II clinical trials.
    Chi Y; Chen CM
    Stat Med; 2008 Dec; 27(29):6175-89. PubMed ID: 18816510
    [TBL] [Abstract][Full Text] [Related]  

  • 95. An extension of the single threshold design for monitoring efficacy and safety in phase II clinical trials.
    Brutti P; Gubbiotti S; Sambucini V
    Stat Med; 2011 Jun; 30(14):1648-64. PubMed ID: 21520453
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Evaluating the efficiency of targeted designs for randomized clinical trials.
    Simon R; Maitournam A
    Clin Cancer Res; 2004 Oct; 10(20):6759-63. PubMed ID: 15501951
    [TBL] [Abstract][Full Text] [Related]  

  • 97. One- and two-stage designs for phase II window studies.
    Chang MN; Devidas M; Anderson J
    Stat Med; 2007 Jun; 26(13):2604-14. PubMed ID: 17211853
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment.
    Filion M; Forget G; Brochu O; Provencher L; Desbiens C; Doyle C; Poirier B; DuRocher M; Camden S; Lemieux J
    Clin Trials; 2012 Oct; 9(5):652-9. PubMed ID: 23060323
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Two-stage randomization designs in drug development.
    Wolbers M; Helterbrand JD
    Stat Med; 2008 Sep; 27(21):4161-74. PubMed ID: 18570274
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The Add-Arm Design for Unimodal Response Curve with Unknown Mode.
    Chang M; Wang J
    J Biopharm Stat; 2015; 25(5):1039-64. PubMed ID: 25331003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.